Prices for Levetiracetam (Bulk) CFR Los Angeles (USD/Tonne) in the US declined in the first half of October 2025 after a rise of 1% in September, owing to lower import prices and softer Chinese quotations, which had affected the spirit of the market. The September increase was the result of stronger Chinese export offers, and the protracted truce in tariffs between the US and China that still left predictable inflows of the API with the limited 30% tariff on imports. However, the changes in source procurement prices in October prompted cautious buying behavior, with agents or pharmaceuticals delaying the replenishment of requirements in view of possible further declines. Analysts suggest that while there is still strong basic demand for Levetiracetam prices are set to decline considerably in the second half of October. A gradual adjustment will probably take place with restrained procurements, limited trade flow, and subdued activity in stocks, with the various parties awaiting clearer signals for price movements before the resumption of bulk purchases is undertaken.
Levetiracetam prices in the US dropped off slightly in the first half of October 2025 - a bit of a surprise considering a modest 1% price increase in September. The recent price drop has largely been driven by cheaper import costs, lower freight charges, and easier-to-come-by supplies from key Asian suppliers, particularly China.
In September 2025, US Levetiracetam prices went up a bit due to stiffer export offers from China and steadier shipping costs, which led to higher landed costs. A 90-day extension of the US-China trade truce into November 10 helped keep a 30% duty cap on pharmaceutical imports in place, which kept the API coming in from Shanghai. The fact that the US dollar went up a bit against the Chinese yuan helped drive up costs for Levetiracetam shipments further, pushing overall prices up. Domestic stocks, which had been piling up in August because of oversupply, started to normalize as distributors and formulation makers began restocking in a more selective way.
The September price rises for Levetiracetam got a boost from consistent demand in the US for the medication. The steady number of people with epilepsy and the ongoing reliance on generic epilepsy meds, where Levetiracetam is the main player, created a stable market for demand. Hospitals and pharmacies just carried on as usual, ordering their Levetiracetam supplies, which kept the market running smoothly.
However, as October 2025 got underway, the Levetiracetam market took another hit downwards. Levetiracetam prices coming in from Chinese producers softened up, due to lower production costs and increased output due to stability in the global supply chain - this all worked to lower landed costs for US buyers and made the price of Levetiracetam drop. Distributors were cautious about short-term market swings, so they held off on buying in bulk until they could get a clearer picture of what the prices were going to do.
The Levetiracetam price drop also coincided with a lack of interest in restocking from downstream pharmaceutical companies. The importers and wholesalers were being cautious too and were preferring to wait until the end of the month before making any substantial purchases or even trading big volumes.
Market experts say that the initial softness we are seeing in the Levetiracetam market is mainly due to import-driven dynamics, but the US market still has a lot of structural resilience due to solid demand and consistent prescribing volumes.
On top of that, the ongoing tariff truce between the US & China is still sending a clear signal that Levetiracetam API is going to be readily available, which in turn helps keep things predictable in the market. However, Chinese exporters are really trying to hold onto their market share, so they're offering US distributors deep discounts on big bulk orders, which is just adding more downward pressure to the Levetiracetam spot prices. Additionally, a decline in freight charges from Asia to the USA further supported the downward trend of Levetiracetam.
According to the experts, Levetiracetam prices in the US are going to plummet in the second half of October 2025. There's going to be a slow correction in the prices as buyers become a lot more cautious about buying. The trade flow will probably stay quiet as distributors just try to avoid getting stuck with too much Levetiracetam inventory, keeping the downward trend going forward in the coming weeks.
